By David Degerming, National Post reporterDecember 9, 2017It’s a study that seems to have the backing of a number of experts, including an academic who says it could have implications for how people manage their own allergies and how we deal with the pandemic.
Antisepsie is a new antihistamine that is currently being tested in a number.
It is being offered as a nasal spray to combat the spread of the coronavirus and its associated respiratory and other health risks.
But it is being tested on an experimental group of patients in the Netherlands.
The study is the first to show it has some positive results.
In fact, some of the patients have shown a reduced risk of developing allergic reactions when they get the spray.
Antisyepsis is the name given to a study published in 2017 that compared the effectiveness of the nasal spray with placebo.
Antijepsis, meanwhile, is a study looking at the effectiveness and safety of a nasal sprays for people with allergies.
But the Dutch study, led by a team led by Dr. Jeroen de Graaf, showed that the antisyepsesic spray had a lower risk of causing allergy than placebo.
De Graaf and his team had hoped to see an effect that was more significant in people who were more likely to have severe asthma, allergic rhinitis or hay fever.
But they weren’t able to replicate their findings in a controlled trial, so the Dutch researchers ran a trial in which a small group of people got a placebo, and then got a spray.
“We did not see an adverse effect in this small group, because we are just using a randomised trial,” de Graf told CBC News in an interview.
“And in a trial with a larger group of subjects, we would expect to see a more positive effect.”
In the study, a total of 24 people with severe allergies were randomly assigned to get either a placebo or a spray, and the results were compared.
The study showed that those who got the spray had an 85 per cent reduction in allergic reactions, compared to those who had gotten the spray without the nasal spray.
The Dutch team found that the nasal nasal spray had no significant effects on the risk of allergic reactions in the group that got the nasal spraying.
The research has been criticized by a number experts who say the study is not representative of the vast majority of people who get their own antihistamines and should be considered for further study.
De Maeyen, an allergist and researcher at the Centre for Clinical Immunology at the University of Amsterdam, said the study was a poor indication of the effectiveness or safety of antisyepsies.
“They are still only testing one group of allergy sufferers, so we don’t know if it would be a useful outcome,” he said.
“This study is clearly not representative.
We need to see larger trials with more people, but at the moment, we can’t say that we can rule out the possibility that the antihistans have any positive effects.”
Researchers say there are some potential limitations to the study.
For one, the study only looked at people who got their own spray.
There is no way to predict the response of a person to another type of medication, so a patient’s response could vary from person to person.
And while de Graaff and his colleagues have been using a trial design for years, the Dutch group has done its own research on the safety and effectiveness of their product.
“It is important to note that this is not a controlled study,” he told CBC.
“This is a clinical trial, and a very limited study, so any results are preliminary.”
Antisyepsia is an allergy treatment, so there is no one way to do it.
If it works for some people, it may work for others, too.
De Geerming has been following the research closely and said it was a significant finding.
“I have to say I’m not surprised,” he wrote in an email to CBC News.
“There are a number indications that there are real benefits in the treatment of allergic rhinosinusitis.”
AntisEpsis and De Geerning have a new study in the works, so it’s still a few more months before they can have a more definitive response.